Akers Biosciences Share Discussion Threads

[lendmeafiver] 29/3/2017 20:40

Thanks, very helpful historic summary, maybe a good time to get in with a small punt.

[lendmeafiver] 29/3/2017 18:53

Bit of momentum building in this company with respect to products and sales, market cap seems remarkably cheap, what am I missing?

[little rascal] 29/3/2017 09:05

c'mon whack it to 500p

[norbus] 29/3/2017 08:45

mcm

what do you expect from a helium balloon? Stocking order will be useful, but no doubt some home office advertising will be expected. Only sales after stocking order will give the better picture. Good luck

[mcmather] 28/3/2017 23:25

This fella suggests that if nasdaq stays above $2.25 - after hours appeared to be $2.30 - there might be more to come:

[mcmather] 28/3/2017 21:29

Starting and ending with Walt; "We hope this is the start of a mutually beneficial relationship between First Check and Akers Bio which could even expand beyond cholesterol and into other areas of rapid testing".

[mcmather] 28/3/2017 21:29

CVS Pharmacy has 9600 outlets / locations according to t'internet.

Rite Aid has 4553 outlets / locations according to t'internet.

Target has 1806 outlets / locations according to t'internet.

Kmart has 735 outlets / locations according to t'internet.

Meijer has 200 outlets / locations according to t'internet.

Giant Eagle has 229 outlets / locations according to t'internet.

Stop & Shop has 422 outlets / locations according to t'internet.

Giant has 200 outlets / locations according to t'internet; assuming this is Giant Food Stores which operates as Giant and Martins.

Shopko has 333 outlets / locations according to t'internet.

Total 16,452 outlets / locations according to t'internet.

[mcmather] 28/3/2017 21:29

The RNS states "Akers Biosciences Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check"

First Check Diagnostics, LLC provides you with the accurate answers you are looking for to those difficult questions in the privacy of your own home.


And First Check Diagnostics, LLC is owned and operated by Alere Inc., which is a major global developer, manufacturer, and marketer of advanced, pioneering consumer and professional medical diagnostic products.


"Alere Inc. is a global manufacturer of rapid point-of-care diagnostic tests. The company was founded in 2001 and is headquartered in Waltham, Massachusetts. As of January 2017, the company has a market capitalization of $3.47 billion with an enterprise value of $5.9 billion".


And "Point-of-care diagnostics is a growing and dynamic industry helping to improve clinical and economic outcomes globally. Alere brings you a variety of expert viewpoints on new innovations, insights, and impacts that are shaping the future of diagnostics around the world"

[mcmather] 28/3/2017 21:29

From the original RNS 1 Dec 2016:

Walt - "We developed the only test marketed in the USA with the capacity to achieve this and we believe that is why First Check - a major force in rapid diagnostics - has chosen to start selling our test through their popular brand. We hope this is the start of a mutually beneficial relationship between First Check and Akers Bio which could even expand beyond cholesterol and into other areas of rapid testing."

According the United States Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the United States have high 'bad cholesterol' and fewer than 1 in every 3 of them has the condition under control.



Tend to agree Norbus - there are similar kind of products in the UK but I doubt that I'd ever buy one. The US though might be interesting; if 10% of the 73.5m US adults alluded to undertook a disposal test and, say, once a month that would loosely equate to 100m tests a year (averaged up). Even if they just got a very small piece of that action it would likely have an impact here. Bit more research to follow:

[little rascal] 28/3/2017 16:02

C'mon

31% only with such spread? Why MMS preventing punters from buying?

This is going to be 1000p per shs.


Who bought GPX from 50p????

[norbus] 28/3/2017 15:47

On the way back to £6; would I buy the test? Not likely but with Americans time will tell

[mcmather] 28/3/2017 14:13

$2.20 (us) = £1.74 approx

[mcmather] 28/3/2017 14:05

" I am delighted that we will soon have this over-the-counter health and wellness product from Akers Bio on the shelves of major US retailers under the distinguished First Check brand."

Won't hold my breath re numbers but certainly no harm getting the product/s on the shelves of US stores.

[werewolfie] 23/3/2017 12:40

We should ask Bellwhiff to return to this forum and add to the fun!!

[wigwammer] 23/3/2017 12:19

With due respect, failing to recognise nearly half of the h2 revenues of the headline product is quite a material omission.

[mcmather] 23/3/2017 10:51

That 40% figure would have been accurate had the $500k from the China deal been accounted for in Q3 2016 and not, as was detailed in their formal results, Q2 2016. Apart from that 'small' oversight...

Still reckon it'll be prudent to avoid any giddiness for the time being. Re the latest TU - "Sales of PIFA Heparin PF/4 Rapid Assay products to U.S. hospitals in H2 2016 enjoyed their strongest ever half year period, providing strong trading momentum moving into the current year."

The figures for H1 2015 were "US sales of flagship test for heparin--induced thrombocytopenia ("HIT") were $898,960". Under the new pricing structure introduced at the start of 2016 that would have equated to approx $1.6m for H1 2015 (H2 2016 being approx $1,1m) whilst the figure for Q4 2016 is still lower than Q1 2016 notwithstanding it having improved from Q2 2016 and Q3 2016.

The conference call should be interesting though.

[wigwammer] 23/3/2017 10:12

"Approx 40% decline in the total sales of the product in the US between H1 2016 and H2 2016?"Hmmm...

[mcmather] 23/3/2017 10:02

I might need to invest in a new calculator...

Q1 2016 - $635,173.

Q2 2016 - $373,702(?).

Q3 2016 - $514,839.

Q4 2016 - $575k approx?

[wigwammer] 23/3/2017 09:41

We already know the h2 figure:"Approximately 87% of product revenue was generated from sales of the Company's flagship PIFA Heparin PF/4 Rapid Assay... Total sales in 2016 associated with this test are expected to be approximately $2.6 million, representing growth of 88% over the prior year."This implies fy ex china sales of $2.1m.H106: sales $1mH206: sales $1.1mThe sequential sales rose, they did not fall as you suggest.

[mcmather] 23/3/2017 09:04

I stand corrected.

H1 2016 - Sales of flagship PIFA Heparin/PF4 Rapid Assay products up 68% to $1,514,255; less $505,380 for the China deal = $1,008,875 net total sales in the US.

H2 2016 - my estimation - Sales of flagship PIFA Heparin/PF4 Rapid Assay products of approx $580,490.

Approx 40% decline in the total sales of the product in the US between H1 2016 and H2 2016?

We should know soon enough:

Thursday, March 23
Next Full Year Results
Akers Bioscience Full Year Results

[wigwammer] 23/3/2017 08:47

"Sales of PIFA Heparin PF/4 Rapid Assay products to U.S. hospitals in H2 2016 enjoyed their strongest ever half year period, providing strong trading momentum moving into the current year." (Gormally)Sequential sales rose, they did not fall as you suggest.The China order is included in the h1 sales figure, not h2 as you suggest, hence leading you to an incorrect conclusion.

[wigwammer] 21/3/2017 16:46

"Pigs can sometimes fly in Walt Disney world"I have little doubt that if the shares rise you will use this as evidence that you called it correctly.

[norbus] 21/3/2017 16:22

Wigwammer

You have no point to prove or otherwise, period; you are just crazed with a delusion of having invested in A JOHNSON & JOHNSON IN THE MAKING. Good luck. Pigs can sometimes fly in Walt Disney world